NSRX 6-K: Cfo change
Filed with the SEC on · accession 0001493152-26-052046
NSRX filed a 6-K (foreign company report) with the SEC on Nov 16, 2026. Nasus Pharma Ltd. appointed Nir Sassi as its new Chief Financial Officer effective November 11, 2026, and entered into an employment agreement with him.
Summary of the filing
Nasus Pharma Ltd. appointed Nir Sassi as its new Chief Financial Officer effective November 11, 2026, and entered into an employment agreement with him. The company issued a press release announcing the appointment on November 16, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for NSRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NSRX?
Click hereFrequently asked questions
What did NSRX file with the SEC on Nov 16, 2026?
NSRX filed a 6-K (Cfo change). Nasus Pharma Ltd. appointed Nir Sassi as its new Chief Financial Officer effective November 11, 2026, and entered into an employment agreement with him. The company issued a press release announcing the appointment on November 16, 2026.
What does a cfo change mean for NSRX stock?
Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Other NSRX SEC filings
- 6-K · SEC filingOct 8, 2026
- 6-K · Secondary offeringSep 18, 2026
- 6-K · Fda approvalSep 14, 2026
- EFFECT · SEC filingSep 11, 2026
- 6-K · SEC filingSep 4, 2026
- EFFECT · SEC filingAug 20, 2026
- 6-K · Cfo changeAug 19, 2026
- 6-K · SEC filingAug 17, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 6-K · Ceo changeJul 28, 2026
Get alerts when NSRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days